Global Animal Stem Cell Therapy

Animal Stem Cell Therapy Comprehensive Study by Type (Dogs, Cats, Horses, Others), Application (Osteoarthritis, Injuries to bones, Joints, Tendons, Ligament, Spinal cord, Others), Sources (Embryonic (ESC), Non-embryonic (adult) stem cells, Induced pluripotent stem cells (IPSC)), End User (Veterinary Hospitals, Research Organizations) Players and Region - Global Market Outlook to 2028

Animal Stem Cell Therapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Animal Stem Cell Therapy Market?

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector. Stem cell therapy is often referred to as regenerative medicine, a technique that enables the body to repair and regenerate damaged tissues. The animal stem cell therapy process involves three steps which include the collection of stem cell samples from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of inflammatory bowel, kidney, liver, heart, and immune-mediated diseases respectively.

Highlights from Animal Stem Cell Therapy Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledMediVet Biologic(United States), VETSTEM BIOPHARMA(United States), Gallant Pet (United States), Celavet(United States), Magellan Stem Cells (Australia), U.S. Stem Cell(United States), ANIMAL CELL THERAPIES(United States), Animal Care Stem(United States) and Cell Therapy Sciences(United Kingdom)


The animal stem cell therapy market can be described as mildly divided. With an extensive piece of players, the animal cell treatment market is encircled by significant competition. Innovative work exercises structure a significant piece of the development scene since they help acquire novel experiences. Activities such as mergers, consolidations, acquisitions, joint endeavors, coordinated efforts, and associations structure the establishment of the development of the animal stem cell therapy treatment market. These exercises assist makers with acquiring impact and in the end help in expanding the development pace of animal stem cell therapy in the market Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Animal Stem Cell Therapy market throughout the forecasted period.

MediVet Biologic(United States), VETSTEM BIOPHARMA(United States), Gallant Pet (United States), Celavet(United States), Magellan Stem Cells (Australia), U.S. Stem Cell(United States), ANIMAL CELL THERAPIES(United States), Animal Care Stem(United States) and Cell Therapy Sciences(United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are VetCell Therapeutics (United States), Animacel (Slovenia) and Aratana Therapeutics (United States).

Animal Stem Cell Therapy Market Segmentation:
ScopeSub-Segments
Application / End UserOsteoarthritis, Injuries to bones, Joints, Tendons, Ligament, Spinal cord and Others
TypeDogs, Cats, Horses and Others
SourcesEmbryonic (ESC),Non-embryonic (adult) stem cells,Induced pluripotent stem cells (IPSC)
End UserVeterinary Hospitals,Research Organizations


On the basis of geography, the market of Animal Stem Cell Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased expenditure on animal health in many countries from all across the globe

Market Growth Drivers:
The growing adoption of pet animals and the rising number of veterinary and everyday pet care institutions is probably going to cultivate the development of the Animal Stem Cell Therapy market, Increasing prevalence of diseases and disorders in animals and Increasing emphasis on providing treatment without side-effects is contributing to the growth of the market

Challenges:
Lack of awareness regarding the treatment using Animal Stem Cell Therapy

Restraints:
High cost associated with animal stem cell therapy

Opportunities:
Increasing Demand for Treatment of Animals and Growing government funding and initiative for the protection of animals and fast approvals of FDA contributing towards the rapid growth of the animal stem cell therapy

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Animal Stem Cell Therapy provider, Government Regulatory and Research Organizations and End-Use Industry

Market Leaders & Development Strategies
In July 2020 Boehringer Ingelheim German-based pharma organization reported gains GST to fortify its foundational microorganism abilities in Animal Health, unites with Belgian biotech organization GST which creates and delivers cutting edge undeveloped cell items for ponies and pets. The securing follows two years of a fruitful organization that brought the principal ever enlisted undeveloped cell-based veterinary medication to the European market. The choice to secure GST is completely lined up with part of Boehringer Ingelheim's Animal Health methodology, planning to reinforce its portfolio abilities to quicken advancement and development.
In October 2019 Gallant an animal biotech organization set to help pets live on with better and more joyful lives Launches Stem Cell Banking for Dogs Nationwide. The organization has built up the first and only non-obtrusive approach to gathering immature microorganisms, which have been utilized to treat sicknesses going from torn tendons to joint pain to kidney illness.


Report Objectives / Segmentation Covered

By Type
  • Dogs
  • Cats
  • Horses
  • Others
By Application
  • Osteoarthritis
  • Injuries to bones
  • Joints
  • Tendons
  • Ligament
  • Spinal cord
  • Others
By Sources
  • Embryonic (ESC)
  • Non-embryonic (adult) stem cells
  • Induced pluripotent stem cells (IPSC)

By End User
  • Veterinary Hospitals
  • Research Organizations

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The growing adoption of pet animals and the rising number of veterinary and everyday pet care institutions is probably going to cultivate the development of the Animal Stem Cell Therapy market
      • 3.2.2. Increasing prevalence of diseases and disorders in animals
      • 3.2.3. Increasing emphasis on providing treatment without side-effects is contributing to the growth of the market
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness regarding the treatment using Animal Stem Cell Therapy
    • 3.4. Market Trends
      • 3.4.1. Increased expenditure on animal health in many countries from all across the globe
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Animal Stem Cell Therapy, by Type, Application, Sources, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Animal Stem Cell Therapy (Value)
      • 5.2.1. Global Animal Stem Cell Therapy by: Type (Value)
        • 5.2.1.1. Dogs
        • 5.2.1.2. Cats
        • 5.2.1.3. Horses
        • 5.2.1.4. Others
      • 5.2.2. Global Animal Stem Cell Therapy by: Application (Value)
        • 5.2.2.1. Osteoarthritis
        • 5.2.2.2. Injuries to bones
        • 5.2.2.3. Joints
        • 5.2.2.4. Tendons
        • 5.2.2.5. Ligament
        • 5.2.2.6. Spinal cord
        • 5.2.2.7. Others
      • 5.2.3. Global Animal Stem Cell Therapy by: Sources (Value)
        • 5.2.3.1. Embryonic (ESC)
        • 5.2.3.2. Non-embryonic (adult) stem cells
        • 5.2.3.3. Induced pluripotent stem cells (IPSC)
      • 5.2.4. Global Animal Stem Cell Therapy by: End User (Value)
        • 5.2.4.1. Veterinary Hospitals
        • 5.2.4.2. Research Organizations
      • 5.2.5. Global Animal Stem Cell Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Animal Stem Cell Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. MediVet Biologic(United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. VETSTEM BIOPHARMA(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gallant Pet (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celavet(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Magellan Stem Cells (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. U.S. Stem Cell(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ANIMAL CELL THERAPIES(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Animal Care Stem(United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cell Therapy Sciences(United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Animal Stem Cell Therapy Sale, by Type, Application, Sources, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Animal Stem Cell Therapy (Value)
      • 7.2.1. Global Animal Stem Cell Therapy by: Type (Value)
        • 7.2.1.1. Dogs
        • 7.2.1.2. Cats
        • 7.2.1.3. Horses
        • 7.2.1.4. Others
      • 7.2.2. Global Animal Stem Cell Therapy by: Application (Value)
        • 7.2.2.1. Osteoarthritis
        • 7.2.2.2. Injuries to bones
        • 7.2.2.3. Joints
        • 7.2.2.4. Tendons
        • 7.2.2.5. Ligament
        • 7.2.2.6. Spinal cord
        • 7.2.2.7. Others
      • 7.2.3. Global Animal Stem Cell Therapy by: Sources (Value)
        • 7.2.3.1. Embryonic (ESC)
        • 7.2.3.2. Non-embryonic (adult) stem cells
        • 7.2.3.3. Induced pluripotent stem cells (IPSC)
      • 7.2.4. Global Animal Stem Cell Therapy by: End User (Value)
        • 7.2.4.1. Veterinary Hospitals
        • 7.2.4.2. Research Organizations
      • 7.2.5. Global Animal Stem Cell Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Animal Stem Cell Therapy: by Type(USD Million)
  • Table 2. Animal Stem Cell Therapy Dogs , by Region USD Million (2017-2022)
  • Table 3. Animal Stem Cell Therapy Cats , by Region USD Million (2017-2022)
  • Table 4. Animal Stem Cell Therapy Horses , by Region USD Million (2017-2022)
  • Table 5. Animal Stem Cell Therapy Others , by Region USD Million (2017-2022)
  • Table 6. Animal Stem Cell Therapy: by Application(USD Million)
  • Table 7. Animal Stem Cell Therapy Osteoarthritis , by Region USD Million (2017-2022)
  • Table 8. Animal Stem Cell Therapy Injuries to bones , by Region USD Million (2017-2022)
  • Table 9. Animal Stem Cell Therapy Joints , by Region USD Million (2017-2022)
  • Table 10. Animal Stem Cell Therapy Tendons , by Region USD Million (2017-2022)
  • Table 11. Animal Stem Cell Therapy Ligament , by Region USD Million (2017-2022)
  • Table 12. Animal Stem Cell Therapy Spinal cord , by Region USD Million (2017-2022)
  • Table 13. Animal Stem Cell Therapy Others , by Region USD Million (2017-2022)
  • Table 14. Animal Stem Cell Therapy: by Sources(USD Million)
  • Table 15. Animal Stem Cell Therapy Embryonic (ESC) , by Region USD Million (2017-2022)
  • Table 16. Animal Stem Cell Therapy Non-embryonic (adult) stem cells , by Region USD Million (2017-2022)
  • Table 17. Animal Stem Cell Therapy Induced pluripotent stem cells (IPSC) , by Region USD Million (2017-2022)
  • Table 18. Animal Stem Cell Therapy: by End User(USD Million)
  • Table 19. Animal Stem Cell Therapy Veterinary Hospitals , by Region USD Million (2017-2022)
  • Table 20. Animal Stem Cell Therapy Research Organizations , by Region USD Million (2017-2022)
  • Table 21. South America Animal Stem Cell Therapy, by Country USD Million (2017-2022)
  • Table 22. South America Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 23. South America Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 24. South America Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 25. South America Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 26. Brazil Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 27. Brazil Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 28. Brazil Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 29. Brazil Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 30. Argentina Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 31. Argentina Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 32. Argentina Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 33. Argentina Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 34. Rest of South America Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 35. Rest of South America Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 36. Rest of South America Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 37. Rest of South America Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 38. Asia Pacific Animal Stem Cell Therapy, by Country USD Million (2017-2022)
  • Table 39. Asia Pacific Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 40. Asia Pacific Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 41. Asia Pacific Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 42. Asia Pacific Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 43. China Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 44. China Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 45. China Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 46. China Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 47. Japan Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 48. Japan Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 49. Japan Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 50. Japan Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 51. India Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 52. India Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 53. India Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 54. India Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 55. South Korea Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 56. South Korea Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 57. South Korea Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 58. South Korea Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 59. Taiwan Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 60. Taiwan Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 61. Taiwan Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 62. Taiwan Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 63. Australia Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 64. Australia Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 65. Australia Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 66. Australia Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 71. Europe Animal Stem Cell Therapy, by Country USD Million (2017-2022)
  • Table 72. Europe Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 73. Europe Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 74. Europe Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 75. Europe Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 76. Germany Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 77. Germany Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 78. Germany Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 79. Germany Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 80. France Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 81. France Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 82. France Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 83. France Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 84. Italy Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 85. Italy Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 86. Italy Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 87. Italy Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 88. United Kingdom Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 89. United Kingdom Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 90. United Kingdom Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 91. United Kingdom Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 92. Netherlands Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 93. Netherlands Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 94. Netherlands Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 95. Netherlands Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 96. Rest of Europe Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 97. Rest of Europe Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 98. Rest of Europe Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 99. Rest of Europe Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 100. MEA Animal Stem Cell Therapy, by Country USD Million (2017-2022)
  • Table 101. MEA Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 102. MEA Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 103. MEA Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 104. MEA Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 105. Middle East Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 106. Middle East Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 107. Middle East Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 108. Middle East Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 109. Africa Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 110. Africa Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 111. Africa Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 112. Africa Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 113. North America Animal Stem Cell Therapy, by Country USD Million (2017-2022)
  • Table 114. North America Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 115. North America Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 116. North America Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 117. North America Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 118. United States Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 119. United States Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 120. United States Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 121. United States Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 122. Canada Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 123. Canada Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 124. Canada Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 125. Canada Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 126. Mexico Animal Stem Cell Therapy, by Type USD Million (2017-2022)
  • Table 127. Mexico Animal Stem Cell Therapy, by Application USD Million (2017-2022)
  • Table 128. Mexico Animal Stem Cell Therapy, by Sources USD Million (2017-2022)
  • Table 129. Mexico Animal Stem Cell Therapy, by End User USD Million (2017-2022)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Animal Stem Cell Therapy: by Type(USD Million)
  • Table 140. Animal Stem Cell Therapy Dogs , by Region USD Million (2023-2028)
  • Table 141. Animal Stem Cell Therapy Cats , by Region USD Million (2023-2028)
  • Table 142. Animal Stem Cell Therapy Horses , by Region USD Million (2023-2028)
  • Table 143. Animal Stem Cell Therapy Others , by Region USD Million (2023-2028)
  • Table 144. Animal Stem Cell Therapy: by Application(USD Million)
  • Table 145. Animal Stem Cell Therapy Osteoarthritis , by Region USD Million (2023-2028)
  • Table 146. Animal Stem Cell Therapy Injuries to bones , by Region USD Million (2023-2028)
  • Table 147. Animal Stem Cell Therapy Joints , by Region USD Million (2023-2028)
  • Table 148. Animal Stem Cell Therapy Tendons , by Region USD Million (2023-2028)
  • Table 149. Animal Stem Cell Therapy Ligament , by Region USD Million (2023-2028)
  • Table 150. Animal Stem Cell Therapy Spinal cord , by Region USD Million (2023-2028)
  • Table 151. Animal Stem Cell Therapy Others , by Region USD Million (2023-2028)
  • Table 152. Animal Stem Cell Therapy: by Sources(USD Million)
  • Table 153. Animal Stem Cell Therapy Embryonic (ESC) , by Region USD Million (2023-2028)
  • Table 154. Animal Stem Cell Therapy Non-embryonic (adult) stem cells , by Region USD Million (2023-2028)
  • Table 155. Animal Stem Cell Therapy Induced pluripotent stem cells (IPSC) , by Region USD Million (2023-2028)
  • Table 156. Animal Stem Cell Therapy: by End User(USD Million)
  • Table 157. Animal Stem Cell Therapy Veterinary Hospitals , by Region USD Million (2023-2028)
  • Table 158. Animal Stem Cell Therapy Research Organizations , by Region USD Million (2023-2028)
  • Table 159. South America Animal Stem Cell Therapy, by Country USD Million (2023-2028)
  • Table 160. South America Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 161. South America Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 162. South America Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 163. South America Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 164. Brazil Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 165. Brazil Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 166. Brazil Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 167. Brazil Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 168. Argentina Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 169. Argentina Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 170. Argentina Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 171. Argentina Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 172. Rest of South America Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 173. Rest of South America Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 174. Rest of South America Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 175. Rest of South America Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 176. Asia Pacific Animal Stem Cell Therapy, by Country USD Million (2023-2028)
  • Table 177. Asia Pacific Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 178. Asia Pacific Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 179. Asia Pacific Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 180. Asia Pacific Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 181. China Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 182. China Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 183. China Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 184. China Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 185. Japan Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 186. Japan Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 187. Japan Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 188. Japan Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 189. India Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 190. India Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 191. India Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 192. India Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 193. South Korea Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 194. South Korea Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 195. South Korea Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 196. South Korea Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 197. Taiwan Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 198. Taiwan Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 199. Taiwan Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 200. Taiwan Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 201. Australia Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 202. Australia Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 203. Australia Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 204. Australia Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 209. Europe Animal Stem Cell Therapy, by Country USD Million (2023-2028)
  • Table 210. Europe Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 211. Europe Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 212. Europe Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 213. Europe Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 214. Germany Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 215. Germany Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 216. Germany Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 217. Germany Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 218. France Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 219. France Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 220. France Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 221. France Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 222. Italy Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 223. Italy Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 224. Italy Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 225. Italy Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 226. United Kingdom Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 227. United Kingdom Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 228. United Kingdom Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 229. United Kingdom Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 230. Netherlands Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 231. Netherlands Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 232. Netherlands Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 233. Netherlands Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 234. Rest of Europe Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 235. Rest of Europe Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 236. Rest of Europe Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 237. Rest of Europe Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 238. MEA Animal Stem Cell Therapy, by Country USD Million (2023-2028)
  • Table 239. MEA Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 240. MEA Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 241. MEA Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 242. MEA Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 243. Middle East Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 244. Middle East Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 245. Middle East Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 246. Middle East Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 247. Africa Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 248. Africa Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 249. Africa Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 250. Africa Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 251. North America Animal Stem Cell Therapy, by Country USD Million (2023-2028)
  • Table 252. North America Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 253. North America Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 254. North America Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 255. North America Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 256. United States Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 257. United States Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 258. United States Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 259. United States Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 260. Canada Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 261. Canada Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 262. Canada Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 263. Canada Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 264. Mexico Animal Stem Cell Therapy, by Type USD Million (2023-2028)
  • Table 265. Mexico Animal Stem Cell Therapy, by Application USD Million (2023-2028)
  • Table 266. Mexico Animal Stem Cell Therapy, by Sources USD Million (2023-2028)
  • Table 267. Mexico Animal Stem Cell Therapy, by End User USD Million (2023-2028)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Animal Stem Cell Therapy: by Type USD Million (2017-2022)
  • Figure 5. Global Animal Stem Cell Therapy: by Application USD Million (2017-2022)
  • Figure 6. Global Animal Stem Cell Therapy: by Sources USD Million (2017-2022)
  • Figure 7. Global Animal Stem Cell Therapy: by End User USD Million (2017-2022)
  • Figure 8. South America Animal Stem Cell Therapy Share (%), by Country
  • Figure 9. Asia Pacific Animal Stem Cell Therapy Share (%), by Country
  • Figure 10. Europe Animal Stem Cell Therapy Share (%), by Country
  • Figure 11. MEA Animal Stem Cell Therapy Share (%), by Country
  • Figure 12. North America Animal Stem Cell Therapy Share (%), by Country
  • Figure 13. Global Animal Stem Cell Therapy share by Players 2022 (%)
  • Figure 14. Global Animal Stem Cell Therapy share by Players (Top 3) 2022(%)
  • Figure 15. Global Animal Stem Cell Therapy share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. MediVet Biologic(United States) Revenue, Net Income and Gross profit
  • Figure 18. MediVet Biologic(United States) Revenue: by Geography 2022
  • Figure 19. VETSTEM BIOPHARMA(United States) Revenue, Net Income and Gross profit
  • Figure 20. VETSTEM BIOPHARMA(United States) Revenue: by Geography 2022
  • Figure 21. Gallant Pet (United States) Revenue, Net Income and Gross profit
  • Figure 22. Gallant Pet (United States) Revenue: by Geography 2022
  • Figure 23. Celavet(United States) Revenue, Net Income and Gross profit
  • Figure 24. Celavet(United States) Revenue: by Geography 2022
  • Figure 25. Magellan Stem Cells (Australia) Revenue, Net Income and Gross profit
  • Figure 26. Magellan Stem Cells (Australia) Revenue: by Geography 2022
  • Figure 27. U.S. Stem Cell(United States) Revenue, Net Income and Gross profit
  • Figure 28. U.S. Stem Cell(United States) Revenue: by Geography 2022
  • Figure 29. ANIMAL CELL THERAPIES(United States) Revenue, Net Income and Gross profit
  • Figure 30. ANIMAL CELL THERAPIES(United States) Revenue: by Geography 2022
  • Figure 31. Animal Care Stem(United States) Revenue, Net Income and Gross profit
  • Figure 32. Animal Care Stem(United States) Revenue: by Geography 2022
  • Figure 33. Cell Therapy Sciences(United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Cell Therapy Sciences(United Kingdom) Revenue: by Geography 2022
  • Figure 35. Global Animal Stem Cell Therapy: by Type USD Million (2023-2028)
  • Figure 36. Global Animal Stem Cell Therapy: by Application USD Million (2023-2028)
  • Figure 37. Global Animal Stem Cell Therapy: by Sources USD Million (2023-2028)
  • Figure 38. Global Animal Stem Cell Therapy: by End User USD Million (2023-2028)
  • Figure 39. South America Animal Stem Cell Therapy Share (%), by Country
  • Figure 40. Asia Pacific Animal Stem Cell Therapy Share (%), by Country
  • Figure 41. Europe Animal Stem Cell Therapy Share (%), by Country
  • Figure 42. MEA Animal Stem Cell Therapy Share (%), by Country
  • Figure 43. North America Animal Stem Cell Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • MediVet Biologic(United States)
  • VETSTEM BIOPHARMA(United States)
  • Gallant Pet (United States)
  • Celavet(United States)
  • Magellan Stem Cells (Australia)
  • U.S. Stem Cell(United States)
  • ANIMAL CELL THERAPIES(United States)
  • Animal Care Stem(United States)
  • Cell Therapy Sciences(United Kingdom)
Additional players considered in the study are as follows:
VetCell Therapeutics (United States) , Animacel (Slovenia) , Aratana Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Apr 2023 220 Pages 50 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Animal Stem Cell Therapy Quantitative research analysis
Global Animal Stem Cell Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"The growing adoption of pet animals and the rising number of veterinary and everyday pet care institutions is probably going to cultivate the development of the Animal Stem Cell Therapy market " is seen as one of major growth factors of Animal Stem Cell Therapy Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Animal Stem Cell Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Animal Stem Cell Therapy Report?

Have a Query? Click Here

Other Related Reports

Neuropathy Pain Treatment Comprehensive Study by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain,...
$ 3750
Vitamin Deficiency Treatment Comprehensive Study by Type (Multivitamin Deficiency Treatment, Single Vitamin Deficiency Treatment), End Users (Adults, Kids), Route of Administration (Oral, Parenteral)...
$ 3650
Bronchitis Treatment Comprehensive Study by Type (Acute Bronchitis, Chronic Bronchitis), Treatment (Drugs, Oxygen Therapy), Drugs Class (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Other), ...
$ 3450
Preterm Labor Treatment Comprehensive Study by Type (Devices, Cervical Cerclage, Vaginal Pessaries, Drug), Application (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes, Pharmacy), Distributi...
$ 3750
Parkinson's Disease Treatment Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics), Drug Class (Carbido...
$ 3650
Mantle Cell Lymphoma Treatment Comprehensive Study by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11, Others), Application (Hospital, Clinic, Others), Route of Admin...
$ 3650